Success Metrics

Clinical Success Rate
100.0%

Based on 8 completed trials

Completion Rate
100%(8/8)
Active Trials
0(0%)
Results Posted
75%(6 trials)

Phase Distribution

Ph phase_2
1
11%
Ph not_applicable
1
11%
Ph phase_3
2
22%
Ph phase_1
2
22%
Ph phase_4
3
33%

Phase Distribution

2

Early Stage

1

Mid Stage

5

Late Stage

Phase Distribution9 total trials
Phase 1Safety & dosage
2(22.2%)
Phase 2Efficacy & side effects
1(11.1%)
Phase 3Large-scale testing
2(22.2%)
Phase 4Post-market surveillance
3(33.3%)
N/ANon-phased studies
1(11.1%)

Highest Phase Reached

Phase 4

Trial Status & Enrollment

Completion Rate

88.9%

8 of 9 finished

Non-Completion Rate

11.1%

1 ended early

Currently Active

0

trials recruiting

Total Trials

9

all time

Status Distribution
Completed(8)
Terminated(1)

Detailed Status

Completed8
Withdrawn1

Development Timeline

Analytics

Development Status

Total Trials
9
Active
0
Success Rate
100.0%
Most Advanced
Phase 4

Trials by Phase

Phase 12 (22.2%)
Phase 21 (11.1%)
Phase 32 (22.2%)
Phase 43 (33.3%)
N/A1 (11.1%)

Trials by Status

withdrawn111%
completed889%

Recent Activity

Clinical Trials (9)

Drug Details

Intervention Type
DRUG
Total Trials
9